Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1207

Shown on this page

Current sort

Live official records

Conditions: Glioblastoma, Gliosarcoma
Interventions: Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide; Drug · Procedure · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 70 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 418
States / cities: Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more

Conditions: Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
Interventions: Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy; Other · Procedure · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 624
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 594
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more

Conditions: Uterine Cancer
Interventions: Not listed
Lead sponsor: PinkDx, Inc.; Industry
Eligibility: 45 Years to 100 Years · Female only
Enrollment: 4,500 participants
Timeline: 2024 – 2031
U.S. locations: 16
States / cities: Birmingham, Alabama • San Carlos, California • Orlando, Florida + 12 more

Conditions: Heart Failure, Transplant; Failure, Heart
Interventions: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS); Device
Lead sponsor: XVIVO Perfusion; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions: ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration; Drug · Procedure · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 22 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Lipoma
Interventions: STARMed VIVA Combo RF System; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Modeling of Recruitment Curves
Interventions: Algorithm: Uniform Sampling, Algorithm: hbMEP-adaptive algorithm (version 1), Algorithm: hbMEP-adaptive algorithm (version 2), ML-PEST, MagPro X100 Transcranial Magnetic Stimulation, Digitimer DS8R Transcutaneous Electrical stimulation; Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Glomerular Filtration Rate, Heart Failure
Interventions: Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR), Iohexol; Device · Drug
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibroadenoma, Breast Cancer Stage I
Interventions: Harmonic motion imaging guided focused ultrasound (HMIgFUS), Microbubble-mediated Low Intensity Focused Ultrasound (LIFU), Microbubbles; Procedure · Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 11 more

Conditions: Alzheimer Disease, Hearing Loss, Cognitive Impairment
Interventions: Hearing Intervention, Health Education Intervention; Device · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

About this Columbia University Irving Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Columbia University Irving Medical Center

Filter and sort this campus

Live official records

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Investigations of Reproductive Cancers in Women

XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

RFA for Superficial Lipomas

Adaptive Recruitment Curve Analysis Using Bayesian Modeling

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Early Age-Related Hearing Loss Investigation (EARHLI)

About this Columbia University Irving Medical Center institution page